HDAC inhibition by SNDX-275 (Entinostat) restores expression of silenced leukemia-associated transcription factors Nur77 and Nor1 and of key pro-apoptotic proteins in AML

Leukemia

Volumn 27, Issue 6, 2013, Pages 1358-1368

  Zhou, L ^a   Ruvolo, V R ^a   McQueen, T ^a   Chen, W ^a   Samudio, I J ^a   Conneely, O ^a   Konopleva, M ^b   Andreeff, M ^a  

^a UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

^b BAYLOR COLLEGE OF MEDICINE   (United States)

Author keywords

AML; apoptosis; Nur77 Nor1; SNDX 275

Indexed keywords

BIM PROTEIN; DEATH RECEPTOR; ENTINOSTAT; NUCLEAR RECEPTOR NOR1; NUCLEAR RECEPTOR NUR77; PROTEIN C JUN; PROTEIN NOXA; TRANSCRIPTION FACTOR; TRANSCRIPTION FACTOR AP 1; TRANSCRIPTION FACTOR JUNB; UNCLASSIFIED DRUG;

ACUTE GRANULOCYTIC LEUKEMIA; ARTICLE; CANCER CHEMOTHERAPY; CLINICAL ARTICLE; CONTROLLED STUDY; GENE SILENCING; HUMAN; HUMAN CELL; PRIORITY JOURNAL; RECEPTOR DOWN REGULATION; RECEPTOR UPREGULATION;

ANTINEOPLASTIC AGENTS; APOPTOSIS; BASE SEQUENCE; BENZAMIDES; BLOTTING, WESTERN; DNA PRIMERS; FLOW CYTOMETRY; GENE SILENCING; HISTONE DEACETYLASE INHIBITORS; HUMANS; LEUKEMIA, MYELOID, ACUTE; MEMBRANE TRANSPORT PROTEINS; NEOPLASTIC STEM CELLS; NUCLEAR RECEPTOR SUBFAMILY 4, GROUP A, MEMBER 1; PYRIDINES;

EID: 84878898998     PISSN: 08876924     EISSN: 14765551     Source Type: Journal    
DOI: 10.1038/leu.2012.366     Document Type: Article

References (51)

1. Stone RM, O'Donnell MR, Sekeres MA. Acute myeloid leukemia. Hematology 2004; 1: 98-117.
2. Mullican SE, Zhang S, Konopleva M, Ruvolo V, Andreeff M, Milbrandt J et al. Abrogation of nuclear receptors Nr4a3 andNr4a1 leads to development of acute myeloid leukemia. Nat Med 2007; 13: 730-735. (Pubitemid 46889752)
3. Ramirez-Herrick AM, Mullican SE, Sheehan AM, Conneely OM. Reduced NR4A gene dosage leads to mixed myelodysplastic/myeloproliferative neoplasms in mice. Blood 2011; 117: 2681-2690.
4. Kolluri SK, Bruey-Sedano N, Cao X, Lin B, Lin F, Han Y-H et al. Mitogenic effect of orphan receptor TR3 and its regulation by MEKK1 in lung cancer cells. Mol Cell Biol 2003; 23: 8651-8667. (Pubitemid 37433369)
5. Pei L, Castrillo A, Chen M, Hoffmann A, Tontonoz P. Induction of NR4A orphan nuclear receptor expression in macrophages in response to inflammatory stimuli. J Biol Chem 2005; 280: 29256-29262. (Pubitemid 41161379)
6. Pei L, Castrillo A, Tontonoz P. Regulation of macrophage inflammatory gene expression by the orphan nuclear receptor Nur77. Mol Endocrinol 2006; 20: 786-794.
7. Chao LC, Bensinger SJ, Villanueva CJ, Wroblewski K, Tontonoz P. Inhibition of adipocyte differentiation by Nur77, Nurr1 and Nor1. Mol Endocrinol 2008; 22: 2596-2608.
8. Thompson J, Winoto A. During negative selection, Nur77 family proteins translocate to mitochondria where they associate with Bcl-2 and expose its proapoptotic BH3 domain. J Exp Med 2008; 205: 1029-1036. (Pubitemid 351679679)
9. Sibayama-Imazu T, Fujisawa Y, Masuda Y, Aiuchi T, Nakajo S, Itabe H et al. Induction of apoptosis in PA-1 ovarian cancer cells by vitamin K2 is associated with an increase in the level of TR3/Nur77 and its accumulation in mitochondria and nuclei. J Cancer Res Clin Oncol 2008; 134: 803-812.
10. Chen Y-L, Jian M-H, Lin C-C, Kang J-C, Chen S-P, Lin P-C et al. The induction of orphan nuclear receptor Nur77 expression by n-butylenephthalide as pharmaceuticals on hepatocellular carcinoma cell therapy. Mol Pharmacol 2008; 74: 1046-1058.
11. Ye X-f, Wu Q, Liu S, Lin X-f, Zhang B, Wu J-f et al. Distinct role and functional mode of TR3 and RAR[alpha] in mediating ATRA-induced signalling pathway in breast and gastric cancer cells. Int J Biochem Cell Biol 2004; 36: 98-113. (Pubitemid 37338476)
12. Lee S, Wesselschmidt R, Linette G, Kanagawa O, Russell J, Milbrandt J. Unimpaired thymic and peripheral T cell death in mice lacking the nuclear receptor NGFI-B (Nur77). Science 1995; 269: 532-535.
13. Ponnio T, Burton Q, Pereira FA, Wu DK, Conneely OM. The nuclear receptor Nor-1 is essential for proliferation of the semicircular canals of the mouse inner ear. Mol Cell Biol 2002; 22: 935-945. (Pubitemid 34053070)
14. Winoto A, Littman DR. Nuclear hormone receptors in T lymphocytes. Cell 2002; 109(Supple 1): S57-S66. (Pubitemid 34457852)
15. Li Q-X, Ke N, Sundaram R, Wong-Staal F. NR4A1, 2, 3-an orphan nuclear hormone receptor family involved in cell apoptosis and carcinogenesis. Histol Histopathol 2006; 21: 533-540.
16. Zhang J, DeYoung A, Kasler HG, Kabra NH, Kuang AA, Diehl G et al. Receptormediated apoptosis in T lymphocytes. Cold Spring Harb Symp Quant Biol 1999; 64: 363-371.
17. Philips A, Lesage S, Gingras R, Maira MH, Gauthier Y, Hugo P et al. Novel dimeric Nur77 signaling mechanism in endocrine and lymphoid cells. Mol Cell Biol 1997; 17: 5946-5951. (Pubitemid 27411101)
18. Esteller M. CpG island hypermethylation and tumor suppressor genes: a booming present, a brighter future. Oncogene 2002; 21: 5427-5440. (Pubitemid 34983479)
19. Fraga MF, Ballestar E, Villar-Garea A, Boix-Chornet M, Espada J, Schotta G et al. Loss of acetylation at Lys16 and trimethylation at Lys20 of histone H4 is a common hallmark of human cancer. Nat Genet 2005; 37: 391-400.
20. Giles RH, Peters DJM, Breuning MH. Conjunction dysfunction: CBP/p300 in human disease. Trends Genet 1998; 14: 178-183. (Pubitemid 28244241)
21. Marks PA, Rifkind RA, Richon VM, Breslow R, Miller T, Kelly WK. Histone deacetylases and cancer: causes and therapies. Nat Rev Cancer 2001; 1: 194-202. (Pubitemid 33741894)
22. Sakai K, Nagahara H, Abe K, Obata H. Loss of heterozygosity on chromosome 16 in hepatocellular carcinoma. J Gastroenterol Hepatol 1992; 7: 288-292.
23. Borrow J, Stanton VP, Andresen JM, Becher R, Behm FG, Chaganti RSK et al. The translocation t(8;16)(p11;p13) of acute myeloid leukaemia fuses a putative acetyltransferase to the CREB-binding protein. Nat Genet 1996; 14: 33-41.
24. Ikeda A, Shankar DB, Watanabe M, Tamanoi F, Moore TB, Sakamoto KM. Molecular targets and the treatment of myeloid leukemia. Mol Genet Metab 2006; 88: 216-224. (Pubitemid 43977814)
25. Rowley JD, Reshmi S, Sobulo O, Musvee T, Anastasi J, Raimondi S et al. All patients with the t(11; 16)(q23; p13.3) that involves MLL and CBP have treatment-related hematologic disorders. Blood 1997; 90: 535-541. (Pubitemid 27299092)
26. Wang J, Hoshino T, Redner RL, Kajigaya S, Liu JM. ETO, fusion partner in t(8;21) acute myeloid leukemia, represses transcription by interaction with the human N-CoR/mSin3/HDAC1 complex. PNAS 1998; 95: 10860-10865. (Pubitemid 28413159)
27. Wang J, Saunthararajah Y, Redner RL, Liu JM. Inhibitors of histone deacetylase relieve ETO-mediated repression and induce differentiation of AML1-ETO leukemia cells. Cancer Res 1999; 59: 2766-2769. (Pubitemid 29283104)
28. Bolden JE, Peart MJ, Johnstone RW. Anticancer activities of histone deacetylase inhibitors. Nat Rev Drug Discov 2006; 5: 769-784. (Pubitemid 44348499)
29. Insinga A, Monestiroli S, Ronzoni S, Gelmetti V, Marchesi F, Viale A et al. Inhibitors of histone deacetylases induce tumor-selective apoptosis through activation of the death receptor pathway. Nat Med 2005; 11: 71-76. (Pubitemid 40215840)
30. Nebbioso A, Clarke N, Voltz E, Germain E, Ambrosino C, Bontempo P et al. Tumor-selective action of HDAC inhibitors involves TRAIL induction in acute myeloid leukemia cells. Nat Med 2005; 11: 77-84. (Pubitemid 40215841)
31. Rosato RR, Almenara JA, Grant S. The histone deacetylase inhibitor ms-275 promotes differentiation or apoptosis in human leukemia cells through a process regulated by generation of reactive oxygen species and induction of p21CIP1/WAF1 1. Cancer Res 2003; 63: 3637-3645. (Pubitemid 36793047)
32. Garcia-Manero G, Assouline S, Cortes J, Estrov Z, Kantarjian H, Yang H et al. Phase 1 study of the oral isotype specific histone deacetylase inhibitor MGCD0103 in leukemia. Blood 2008; 112: 981-989.
33. Garcia-Manero G, Kantarjian HM, Sanchez-Gonzalez B, Yang H, Rosner G, Verstovsek S et al. Phase 1/2 study of the combination of 5-aza-2'-deoxycytidine with valproic acid in patients with leukemia. Blood 2006; 108: 3271-3279.
34. Garcia-Manero G, Yang H, Bueso-Ramos C, Ferrajoli A, Cortes J, Wierda WG et al. Phase 1 study of the histone deacetylase inhibitor vorinostat (suberoylanilide hydroxamic acid (SAHA)) in patients with advanced leukemias and myelodysplastic syndromes. Blood 2008; 111: 1060-1066. (Pubitemid 351213383)
35. Hess-Stumpp H, Bracker TU, Henderson D, Politz O. MS-275, a potent orally available inhibitor of histone deacetylases-the development of an anticancer agent. Int J Biochem Cell Biol 2007; 39: 1388-1405. (Pubitemid 47031032)
36. Konopleva M, Contractor R, Tsao T, Samudio I, Ruvolo PP, Kitada S et al. Mechanisms of apoptosis sensitivity and resistance to the BH3 mimetic ABT-737 in acute myeloid leukemia. Cancer Cell 2006; 10: 375-388. (Pubitemid 44693472)
37. Kojima K, Konopleva M, Tsao T, Nakakuma H, Andreeff M. Concomitant inhibition of Mdm2-p53 interaction and aurora kinases activates the p53-dependent postmitotic checkpoints and synergistically induces p53-mediated mitochondrial apoptosis along with reduced endoreduplication in acute myelogenous leukemia. Blood 2008; 112: 2886-2895.
38. Youn H-D, Sun L, Prywes R, Liu JO. Apoptosis of T Cells mediated by Ca2-induced release of the transcription factor MEF2. Science 1999; 286: 790-793.
39. Youn H-D, Liu JO. Cabin1 represses MEF2-dependent Nur77 expression and T cell apoptosis by controlling association of histone deacetylases and acetylases with MEF2. Immunity 2000; 13: 85-94.
40. Inoue S, Riley J, Gant TW, Dyer MJS, Cohen GM. Apoptosis induced by histone deacetylase inhibitors in leukemic cells is mediated by Bim and Noxa. Leukemia 2007; 21: 1773-1782. (Pubitemid 47086766)
41. Chen J, Fiskus W, Eaton K, Fernandez P, Wang Y, Rao R et al. Cotreatment with BCL-2 antagonist sensitizes cutaneous T-cell lymphoma to lethal action of HDAC7-Nur77-based mechanism. Blood 2009; 113: 4038-4048.
42. Dequiedt F, Kasler H, Fischle W, Kiermer V, Weinstein M, Herndier BG et al. HDAC7, a thymus-specific class II histone deacetylase, regulates Nur77 transcription and TCR-mediated apoptosis. Immunity 2003; 18: 687-698. (Pubitemid 36588585)
43. Scott FL, Fuchs GJ, Boyd SE, Denault J-B, Hawkins CJ, Dequiedt F et al. Caspase-8 cleaves histone deacetylase 7 and abolishes its transcription repressor function. J Biol Chem 2008; 283: 19499-19510.
44. Kang S-A, Na H, Kang H-J, Kim S-H, Lee M-H, Lee M-O. Regulation of Nur77 protein turnover through acetylation and deacetylation induced by p300 and HDAC1. Biochem Pharmacol 2010; 80: 867-873.
45. Ulveling D, Francastel C, Hube F. When one is better than two: RNA with dual functions. Biochimie 2011; 93: 633-644.
46. Colley SM, Leedman PJ. Steroid receptor RNA activator -a nuclear receptor coregulator with multiple partners: Insights and challenges. Biochimie 2011; 93: 1966-1972.
47. Gajjar M, Candeias Marco M, Malbert-Colas L, Mazars A, Fujita J, Olivares-Illana V et al. The p53 mRNA-Mdm2 interaction controls Mdm2 nuclear trafficking and is required for p53 activation following dna damage. Cancer Cell 2012; 21: 25-35.
48. Candeias MM, Malbert-Colas L, Powell DJ, Daskalogianni C, Maslon MM, Naski N et al. p53 mRNA controls p53 activity by managing Mdm2 functions. Nat Cell Biol 2008; 10: 1098-1105.
49. Williams GT, Lau LF. Activation of the inducible orphan receptor gene nur77 by serum growth factors: dissociation of immediate-early and delayed-early responses. Mol Cell Biol 1993; 13: 6124-6136. (Pubitemid 23292607)
50. Romanski A, Bacic B, Bug G, Pfeifer H, Gul H, Remiszewski S et al. Use of a novel histone deacetylase inhibitor to induce apoptosis in cell lines of acute lymphoblastic leukemia. Haematologica 2004; 89: 419-426. (Pubitemid 38798546)
51. Lin B, Kolluri SK, Lin F, Liu W, Han Y-H, Cao X et al. Conversion of Bcl-2 from protector to killer by interaction with nuclear orphan receptor Nur77/TR3. Cell 2004; 116: 527-540. (Pubitemid 38264430)